
LungLife AI
Blood-based tool that has been developed to provide clinicians the information needed to make informed decisions about the management of lung nodules and lung cancer.
Market cap
$1.7m
Enterprise value
($673k)
Share price
£0.04 LLAI.L
Authorizing premium user...